Korean biopharma giant Celltrion has teamed up with artificial intelligence drug design startup Galux to co-develop next-generation autoimmune disease therapies using multispecific antibodies, the companies said Tuesday.
Under the collaboration, Galux will handle AI-based antibody design and early-stage validation, while
Continue Reading on The Korea Herald
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.